GOSH statement on new personalised therapy for children with cancer

Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH)

Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH), says:

“GOSH welcomes the exciting announcement that for children with Acute Lymphoblastic Leukaemia (ALL), CAR-T cell therapy will be made available on the NHS. 

“This is a landmark moment in the treatment of childhood cancer in the UK. GOSH has been at the forefront of cutting edge personalised CAR-T therapy treatment for a number of years developing similar CAR-T therapies for children with ALL. Since 2012, we have treated over 25 patients from all over the UK with CAR-T therapies. In 2015, we treated the first patient worldwide with gene edited  “universal” CAR-T cells. We are continuing to work on improving CAR-T cell therapy including using “next generation” CAR-T cells to further reduce the chance of relapse.

“We believe that personalised cell therapy treatments, which allow us to tailor treatments to individual patients, can be the silver bullet, offering a real chance of success for children who have run out of all other options.”

Professor Amrolia is also a NIHR Research Professor of Transplantation Immunology at UCL Great Ormond Street Institute of Child Health.